Bioextrax AB (BIOEX) AI Stock Analysis

Bioextrax AB

(Nasdaq OMX AB:BIOEX)

Select Model

Rating:42Neutral

Price Target:SEK 2.00▼(-14.53% Downside)

Action:upgraded

Date:10/11/26

The overall score is very low, driven primarily by the company's weak financial health, characterized by persistent losses and significant cash burn. The neutral technical picture and poor valuation metrics further weigh on the score, indicating a high-risk profile with no clear positive catalysts from the provided data.

Positive Factors

Debt-Free Balance SheetZero reported debt reduces refinancing and interest-rate exposure, giving Bioextrax greater financial flexibility than a similarly loss-making business with leverage. This structure can help preserve strategic options while the company works toward commercialization and more sustainable profitability.

Negative Factors

Small and Declining RevenueVery small and declining revenue indicates that Bioextrax has not yet established a durable commercial scale. Continued top-line weakness limits operating leverage, reduces the ability to absorb fixed costs, and makes the company more dependent on successful future commercialization efforts.

Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 115.51M
Dividend Yield: ―
Average Volume (3M): 69.60K
Price to Earnings (P/E): -5.4
Beta (1Y): 0.79
Revenue Growth: -37.50%
EPS Growth: 1.01%
Country: Sweden
Employees: 14
Sector: Industrials
Sector Strength: 63
Industry: Biotechnology

Bioextrax AB Business Overview & Revenue Model

Company Description

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules...

Bioextrax AB Financial Statement Overview

Summary

Financial performance is weak. The income statement shows minimal, volatile revenue and persistent losses. The balance sheet has no debt but equity is declining due to cash burn. Cash flows are deeply negative, indicating a need for future financing.

Income Statement

12Very Negative

Balance Sheet

35Negative

Cash Flow

8Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	360.00K	757.00K	515.00K	2.06M	395.00K	275.76K
Gross Profit	-14.84M	-16.43M	-915.00K	718.00K	-18.64M	-11.29M
EBITDA	-14.16M	-17.24M	-16.18M	-20.65M	-18.19M	-10.18M
Net Income	-14.24M	-17.70M	-17.34M	-21.51M	-18.67M	-10.53M
Balance Sheet
Total Assets	14.49M	24.73M	29.00M	22.52M	37.92M	12.64M
Cash, Cash Equivalents and Short-Term Investments	7.39M	3.93M	17.27M	13.40M	27.53M	8.98M
Total Debt	0	0	0	0	0	0
Total Liabilities	2.51M	3.51M	2.94M	1.98M	6.15M	5.14M
Stockholders Equity	11.98M	21.21M	26.06M	20.54M	31.77M	7.50M
Cash Flow
Free Cash Flow	-23.61M	-26.20M	-18.99M	-24.41M	-24.38M	-9.45M
Operating Cash Flow	-23.34M	-26.05M	-18.78M	-23.31M	-17.60M	-8.48M
Investing Cash Flow	-277.00K	-152.00K	-215.00K	-1.10M	-6.78M	-975.13K
Financing Cash Flow	12.58M	12.86M	22.86M	10.28M	42.94M	16.38M

Bioextrax AB Technical Analysis

Technical Analysis SentimentPositive

Last Price2.34

Price Trends

50DMA2.31Positive

100DMA2.41Negative

200DMA2.52Negative

Market Momentum

MACD-0.02Negative

RSI55.75Neutral

STOCH86.71Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Positive. The current price of 2.34 is above the 20-day moving average (MA) of 2.25, above the 50-day MA of 2.31, and below the 200-day MA of 2.52, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 55.75 is Neutral, neither overbought nor oversold. The STOCH value of 86.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOEX.

Bioextrax AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (63)

Financial Indicators

SE:BIOEX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
SE:NXTCL	46Neutral	SEK 29.07M	-0.60	-81.23%	―	-4.02%	35.86%
SE:SPAGO	43Neutral	SEK 32.09M	-0.85	-106.23%	―	-97.37%	25.28%
SE:ANNX	42Neutral	SEK 57.89M	-1.51	―	―	―	7.33%
SE:BIOEX	42Neutral	SEK 115.51M	-5.39	-116.56%	―	-37.50%	1.01%
SE:BIOVIC.B	41Neutral	SEK 103.68M	-1.44	-75.51%	―	56.06%	63.95%
SE:XINT	39Underperform	SEK 134.36M	-2.67	245.07%	―	-38.46%	9.02%

* Industrials Sector Average

Performance Comparison

SE:BIOEX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:BIOEX	Bioextrax AB	2.34	0.03	1.52%
SE:XINT	Xintela AB	0.16	-0.28	-63.97%
SE:BIOVIC.B	Biovica International AB Class B	0.36	-0.14	-27.47%
SE:NXTCL	NextCell Pharma AB	0.23	-0.66	-74.16%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.11	-72.79%
SE:ANNX	Annexin Pharmaceuticals AB	6.64	-19.56	-74.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 11, 2026

Bioextrax AB AI Stock Analysis